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β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production
of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiology of
Alzheimer’s disease (AD). As a result, BACE1 has emerged as a prime drug target for reducing the levels of Aβ in
the AD brain, and the development of BACE1 inhibitors as therapeutic agents is being vigorously pursued. It has
proven difficult for the pharmaceutical industry to design BACE1 inhibitor drugs that pass the blood–brain barrier,
however this challenge has recently been met and BACE1 inhibitors are now in human clinical trials to test for
safety and efficacy in AD patients and individuals with pre-symptomatic AD. Initial results suggest that some of
these BACE1 inhibitor drugs are well tolerated, although others have dropped out because of toxicity and it is still
too early to know whether any will be effective for the prevention or treatment of AD. Additionally, based on newly
identified BACE1 substrates and phenotypes of mice that lack BACE1, concerns have emerged about potential
mechanism-based side effects of BACE1 inhibitor drugs with chronic administration. It is hoped that a therapeutic
window can be achieved that balances safety and efficacy. This review summarizes the current state of progress in
the development of BACE1 inhibitor drugs and the evaluation of their therapeutic potential for AD.Introduction
The role of β-amyloid in Alzheimer’s disease
The extracellular accumulation of amyloid plaques com-
posed of the β-amyloid (Aβ) peptide represents one of the
two defining lesions in Alzheimer’s disease (AD) brain, the
other being intracellular aggregation of hyperphosphory-
lated tau into neurofibrillary tangles. Recent results indicate
that amyloid deposition begins ~10-20 years before the
onset of dementia, suggesting that cerebral accumulation of
Aβ has as a critical early role in AD pathogenesis [1-3]. If
so, then inhibition of Aβ accumulation in the brain may
benefit AD, if given early enough during the course of the
disease.
Neurons are the major producers of Aβ in the brain,
although glia, in particular astrocytes, may also contribute
to Aβ generation, particularly during physiological stress
that causes glial activation as happens in AD. The forma-
tion of Aβ is a sequential proteolytic process beginning with
the cleavage of amyloid precursor protein (APP) by the β-
secretase enzyme, which generates the amino (N) terminusCorrespondence: r-vassar@northwestern.edu
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C99 (Figure 1A) [4]. Next, γ-secretase cuts C99 to release
Aβ, which is secreted from the cell [5-7]. Interestingly, the
γ-secretase cut is imprecise and creates Aβ isoforms of
different lengths at the carboxy (C) terminus, of which the
longer isoforms are highly associated with AD. Processing
of APP by both β- and γ-secretases is necessary for the
generation of Aβ, suggesting that inhibition or modulation
of either or both of these proteases in the brain should
decrease Aβ levels and be beneficial for AD.
Human genetics studies have greatly informed us about
AD pathogenesis and strongly suggest that cerebral Aβ
accumulation has an essential role in the etiology of AD
[2]. Thus far, over 200 autosomal dominant mis-sense
mutations have been identified in the genes for APP and
presenilin (the γ-secretase catalytic subunit) that are associ-
ated with familial AD (FAD). These FAD mutations are
highly penetrant and without exception increase either the
generation of all Aβ isoforms (total Aβ) or the relative
proportion of the 42-amino acid isoform (Aβ42) that is
more neurotoxic. Notably, FAD mutations in APP are
found very near to the β- and γ-secretase cleavage sites,
and these mutations serve to increase APP processing and
raise levels of total Aβ or Aβ42 specifically. The so-calledensee has exclusive rights to distribute this article, in any medium, for 12 months
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Figure 1 APP processing and Aβ generation and mutations that affect β-secretase cleavage. A. APP is a Type-I membrane protein that is
sequentially cleaved by two aspartic proteases to generate Aβ. First, the β-secretase enzyme cuts APP (1) to create the N-terminus of Aβ. Two
APP fragments are produced: membrane-bound C99 and secreted sAPPβ ectodomain. Second, C99 is cleaved by the γ-secretase enzyme (2) to
generate the C-terminus of Aβ. Aβ is then released into the lumen of the endosome and secreted into the extracellular medium. An intracellular
domain, C59, is also produced. B. The amino acids in and around the Aβ domain of APP are represented as blue circles. Amino acids that affect
β-secretase processing of APP in humans are green circles, within which the wild-type residue is identified by the single-letter amino acid code.
The K670N/M671L (Swedish) and A673V mutations cause FAD by increasing β-secretase cleavage and Aβ production, while the A673T mutation
protects against AD by doing the opposite. All three mutations occur at or within one amino acid of the β-secretase cleavage site. Scissors
indicate cleavage sites of the various secretases.
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mutations in APP are particularly compelling, because they
are positioned precisely at and only 2 amino acids C-
terminal to the β-secretase cleavage site, respectively. These
mutations make the cleavage of APP by the β-secretase
enzyme more efficient, so greater amounts of C99 and total
Aβ are generated (Figure 1B). In contrast, an APP muta-
tion, A673T, has been recently identified that confers
protection against AD and cognitive decline in the elderly
[10]. This mutation, which occurs at the same position as
the A673V mutation that causes FAD, is less efficiently
cleaved by β-secretase so that Aβ generation is decreased
by ~40% [10-12]. Interestingly, most carriers have one copy
of the A673T mutation and likely have a reduction in Aβ
production of only ~20%, yet they are still protected against
AD. This implies proof-of-principle of the strategy that
modest reduction of brain Aβ levels may prevent AD, if
started early enough. Additionally, the Swedish, A673V, and
A673T mutations together strongly suggest that inhibition
of β-secretase cleavage of APP should be beneficial for AD.
Review
The identification of β-secretase as β-site APP cleaving
enzyme (BACE)
Following the discoveries of Aβ and the first APP mutations
that cause FAD, it soon became clear that the β- and γ-
secretase enzymes were prime therapeutic targets for the
development of small molecule inhibitor drugs for thetreatment of AD. Thus, their molecular identities were
vigorously pursued. The properties of Aβ generation and
secretase activities in cells and tissues led to the develop-
ment of cell-free and cell-based assays that could be
exploited for the identification of the secretases. Subse-
quently, five groups independently reported the molecular
cloning of the β-secretase enzyme, which they variously
named β-site APP cleaving enzyme (BACE), Asp2, and
memapsin 2 [13-17] (“BACE” has emerged as the most
common moniker in the literature). Importantly, all of the
groups agreed on the same polypeptide sequence even
though they used different experimental approaches to
identify the β-secretase, lending strong support for the
conclusion that the authentic β-secretase had been cloned.
BACE has all the molecular and cellular characteristics
that had been previously predicted for the β-secretase
in vitro and in vivo [4]. It is a Type I transmembrane
aspartic protease of 501 amino acids in length that is closely
related to the pepsin family of aspartic proteases (Figure 2).
The catalytic domain of BACE harbors two aspartic prote-
ase signature motifs of the sequence DTGS and DSGT that
come together to form the active site of the enzyme. As
required for β-secretase, the BACE active site is topologic-
ally oriented on the same side of the membrane as the
β-secretase cleavage site in APP. Additionally, the activity
of BACE has an acidic pH optimum and the catalytic
domain resides within the lumen of acidic intracellular com-
partments, including endosomes and trans-golgi network
Figure 2 Primary structure of BACE1. BACE1 is a 501 amino acid
Type-I transmembrane aspartic protease. The various subdomains of
BACE1 are indicated by the lines to the right of the structure. Numbers
refer to amino acid positions. The two signature aspartic protease
active site motifs at positions 93 and 289 are shaded yellow. S–S
denote positions of disulfide bridges within the catalytic domain; Ns
represents positions of N-linked glycosylation sites; Rs indicates
positions of acetylated arginine residues; Cs mark positions of S-
palmitoylated cysteine residues; P indicates phosphorylation of serine
498; Ub denotes ubiquitination of lysine 501.
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the CNS, BACE has the correct sequence specificity, and
BACE overexpressed in cells cleaves APP and increases
Aβ production.Soon after the discovery of BACE, a homologue, BACE2,
was identified that has ~64% amino acid similarity to BACE
(henceforth referred to as BACE1) [18]. The extensive
degree of homology between the two enzymes suggested
that BACE2 might also function as a β-secretase. However,
this possibility seemed unlikely because BACE2 is not
expressed to a high level in neurons, in contrast to BACE1
[19,20]. Moreover, BACE2 predominantly cleaves APP
within the Aβ domain, so that the generation of Aβ is
precluded [21-25]. These data, together with the finding
that BACE1 null mice are devoid of Aβ (see below), suggest
BACE2 is not likely to be a β-secretase in the CNS.
Physiological functions of BACE1
BACE1−/− mice
To justify BACE1 inhibitor drug development efforts, it
was necessary to provide in vivo validation that BACE1 is
the primary β-secretase enzyme in the brain. To do so, gene
targeting in embryonic stem cells was used to produce
BACE1 knockout (−/−) mice [26-29]. Initial reports showed
that BACE1−/− mice were viable and fertile and did not
have detectable abnormalities. Their normal morphology
and behavior, tissue histology, and blood cell and clinical
chemistry characteristics suggested that BACE1 inhibition
as a therapeutic approach for AD might lack mechanism-
based toxicities. Additionally, APP overexpressing trans-
genic mice that also lack the BACE1 gene are devoid of
cerebral Aβ, amyloid deposition, and Aβ-associated mem-
ory impairments [20,30-33]. Importantly, these data validate
BACE1 as the major β-secretase in the CNS and indicate
that BACE2 does not compensate for BACE1 loss of
function, at least for the production of Aβ. Furthermore,
they strongly suggested that BACE1 inhibition should be a
safe and effective therapeutic strategy for AD.
Although initial studies of BACE1−/− mice indicated that
BACE1 was not required for viability in vivo, further inves-
tigations were necessary to elucidate the physiological
functions of BACE1 and fully understand the potential for
mechanism-based toxicities of therapeutic BACE1 inhib-
ition. For example, BACE1 protein is highly concentrated
in presynaptic terminals of CNS neurons [34,35], suggesting
that BACE1 has a role in synaptic function. Moreover, in
agreement with high BACE1 expression and presynaptic
localization in neurons, deeper analyses of BACE1−/− mice
have uncovered numerous subtle neuronal phenotypes,
such as axon targeting errors [36-38], reduced myelination
[39-41], memory impairments [20,30,32,42,43], reduced
muscle spindles [44], neurochemical abnormalities [45],
alterations in neurogenesis and astrogenesis [46], increased
age-related neurodegeneration [47], reduced spine density
[48], retinal pathology [49], endophenotypes of schizophre-
nia [48], and seizures [42,47,50] (Table 1). Future investiga-
tions may reveal even more BACE1 null phenotypes. Any
of these BACE1 null phenotypes in theory could represent







Axon guidance defects CHL1 [36-38]
Hyperactivity NRG1 [29,48]
Hypomyelination NRG1 [39-41]
Memory deficits Unknown [17,30,32,42,43]
Insulin sensitivity enhanced Unknown [29,51,52]
Muscle spindle reduction NRG1 [44]
Neurochemical deficits Unknown [45]
Neurodegeneration with age Unknown [47]
Postnatal lethality, growth retardation Unknown [29]
Retinal abnormalities VEGFR1 [49]
Schizophrenia endophenotypes NRG1 [48]
Seizures Navβ2 [42,47,50,53]
Spine density reduction NRG1 [48]





Pancreatic β cell increase Tmem27 [54]
Pigmentation abnormalities PMEL [55]
BACE1/2 double knockout mouse phenotypes
Phenotype References
Similar to BACE1 knockout, except postnatal lethality
is enhanced
[29]
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humans, thus raising a note of caution that therapeutic in-
hibition of BACE1 might not be completely free of toxicity.
Substrates of BACE1
The varied phenotypes of the BACE1−/− mice are likely
the result of abrogated β-secretase processing of different
substrates of BACE1 in addition to APP. Recent proteomic
analyses in cultured primary neurons have identified nu-
merous putative BACE1 substrates that have roles in neur-
onal functions [56,57] (Figure 3). The majority of substrates
of BACE1 are, like APP, Type I membrane proteins, while a
few, like neuregulin 1 (NRG1), have more complex mem-
brane topologies. Cleavage of most substrates by BACE1
releases an ectodomain fragment that diffuses from the cell
in the extracellular milieu. There, it may bind to another
molecule on the same (autocrine) or a different (paracrine)
cell to affect signal transduction or cell-cell interactions.
Perhaps the best studied example is that of BACE1 process-
ing of Type III NRG1, which releases an epidermal growth
factor (EGF)-like domain that binds to the ErbB receptor
on the Schwann cell for the simulation of myelination[39,40,58,59]. Because of the lack of β-secretase processing,
BACE1−/− mice have decreased shedding of the NRG1
EGF domain, which reduces instructive signals to myelinat-
ing cells and leads to hypomyelination.
Another example of β-secretase processing of a neuronal
substrate involves the cleavage of the neural cell adhesion
molecule close homolog of L1 (CHL1) by BACE1. Like
APP, CHL1 is a Type I membrane protein, and it has a
well-known function in axonal outgrowth and neuronal
survival [60,61]. Cleavage of CHL1 by BACE1 liberates a
soluble ectodomain fragment that may bind to neuropilin-1
and semaphorin 3A, two molecules that are involved in
axonal guidance. Thus, the lack of β-secretase processing of
CHL1 might account for the presence of mis-targeted
axons that have been reported in the olfactory bulb and
hippocampus of BACE1 null mice [38,56,57].
Although decreased β-secretase processing of many
BACE1 substrates impairs their function, abrogated cleav-
age of other substrates may potentiate their role in a
physiological process. For example, Jagged 1 (Jag1) is a
Type I membrane protein that is a ligand for the Notch re-
ceptor, which regulates the differentiation of many cell
types in the body. Interestingly, Jag1 is also a BACE1 sub-
strate, and reduced BACE1 cleavage of Jag1 in BACE1−/−
mice increases the levels of Jag1 on the cell surface, which
causes greater than normal stimulation of Notch activity in
the neighboring cell. Consequently, during early develop-
ment Jag1-Notch signaling is increased [62] in radial glial
neural stem cells, which promotes astrogenesis over
neurogenesis [46]. As additional BACE1 substrates and
functions are discovered, the underlying molecular mecha-
nisms of BACE1 null phenotypes and their implications for
mechanism-based toxicities of therapeutic BACE1 inhib-
ition will come into clearer focus.
In addition to cleavage by BACE1, a number of BACE1
substrates undergo ectodomain shedding by proteases in
the A Disintegrin and Metalloproteinase Domain (ADAM)
family. The extent to which a given substrate is processed
by BACE1 verses an ADAM family member varies depend-
ing on the substrate (Figure 3). Some substrates are almost
exclusively cut by BACE1 (e.g., SEZ6, APLP1), while other
substrates are primarily cleaved by the ADAMs (e.g., APP,
neuroligin-1) [56,57]. One would predict from these results
that potential mechanism-based side effects that arise from
therapeutic BACE1 inhibition might derive from deficient
processing of substrates that predominantly undergo ecto-
domain shedding by BACE1 rather than the ADAMs.
Conversely, potential toxicities of BACE1 inhibition may be
less associated with substrates that are primarily cleaved by
ADAM proteases over BACE1.
BACE2−/− mice
The significant amino acid similarity shared by BACE1 and
BACE2 suggests that it may be challenging to develop
Figure 3 Neuronal substrates of BACE1. BACE1 substrates identified in primary cultured neurons are listed from those that are predominantly
cleaved by BACE1 (BACE1 cleavage HIGH; top) to those that are processed by BACE1 at a low level (LOW; bottom). These substrates also are
cleaved by other proteases in the ADAM family, but the ADAM cleavage preference is opposite to that of BACE1. (Adapted from Table I, Ref. [56]).
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fore, the possibility exists that BACE1 inhibitor drugs might
also cause BACE2 mechanism-based side effects in addition
to those of BACE1. To investigate this question, BACE2−/−
mice were produced by gene-targeting. Like BACE1 null
mice, the BACE2−/− mice were initially shown to be viable
and fertile with no reported phenotype [29]. Moreover,
other than enhanced early postnatal lethality, BACE1−/−;
BACE2−/− double knockout mice did not have a more
severe phenotype than the BACE1−/− single knockouts
[29]. These data suggest that cross-inhibition of BACE2
with BACE1 inhibitors might not be associated with
enhanced toxicity in the adult after postnatal development
is completed.
Although BACE2−/− mice initially were reported to be
normal, further investigations have revealed BACE2 loss-of-function phenotypes. Pancreatic β-cells express significant
levels of BACE2. Interestingly, BACE2−/− mice have
increased β-cell mass and insulin levels, and the mice ex-
hibit enhanced glucose regulation [54]. These phenotypes
appear to be the result of abrogated BACE2 cleavage of
pro-proliferative Type I transmembrane protein Tmem27,
a protein involved in the regulation of β-cell mass. Given
these results, inhibition of BACE2 may be beneficial for the
treatment of Type 2 diabetes, although further research
into this hypothesis is necessary.
In addition to the pancreatic phenotype, BACE2−/− mice
on a C57BL/6 genetic background exhibit hypopigmentation
that results in a silvery coat compared to the dark coat of
wild-type C57BL/6 mice. This phenotype is caused by lack
of BACE2 processing of the melanocyte protein PMEL that
is expressed in pigment cells of the skin and eye. BACE2
Table 2 Small molecule BACE1 inhibitors in clinical trials
Company Drug Phase
AstraZeneca/Lilly AZD3293 Phase 2/3
CoMentis CTS-21166 Phase 1
Eisai/Biogen Idec E2609 Phase 2
High Point HPP854 Phase 1
Janssen/Shionogi - - - - - - Phase 1
Lilly LY2886721 Phase 2*
Merck MK-8931 Phase 2/3
Novartis - - - - - - Phase 1
Pfizer PF-05297909 Phase 1
Roche RG7129 Phase 1**
Takeda TAK-070 Phase 1
Vitae/Boehringer Ingelheim VTP-37948 Phase 1
*Terminated due to abnormal liver biochemistry.
**Removed from pipeline.
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that forms a matrix of amyloid fibrils upon which melanin
is deposited [55]. Consequently, abrogated processing of
PMEL in BACE2−/− mice leads to abnormal melanosome
formation and hypopigmentation. These results suggest the
possibility that cross-inhibition of BACE2 by BACE1 inhibi-
tors might cause reduced pigmentation in humans.
Small molecule BACE1 inhibitor drugs and clinical trials
for AD
The extensive validation of BACE1 as the primary β-
secretase enzyme in the CNS has spurred vigorous efforts
to develop small molecule inhibitors of BACE1 in both aca-
demia and industry. The first generation of BACE1 inhibi-
tors consisted of non-cleavable peptide-based transition
state analogs designed after the amino-acid sequence in
APP at which β-secretase cleaves [15,63]. Typically, these
large peptidomimetic molecules are very potent BACE1
inhibitors in vitro, mainly because the large open active site
of BACE1 has evolved to bind polypeptide substrates with
high affinity. Unfortunately, the peptide-based BACE1 in-
hibitors did not possess favorable in vivo pharmacological
properties, such as oral bioavailability, long serum half-life,
or blood–brain barrier (BBB) penetration. As a conse-
quence, investigators have turned toward designing true
small molecule BACE1 inhibitor drugs. However, the devel-
opment of non-peptidic BACE1 inhibitors large enough to
bind with sufficient affinity to the enzymatic active site, yet
small enough to exhibit satisfactory pharmacokinetics and
suitable brain penetration has proven to be very challen-
ging. Moreover, BACE1 inhibitors should have sufficient
lipophilicity to cross both plasma and endosomal mem-
branes for gaining access to the vesicle lumen where the
BACE1 active site is located.
A crucial advance in small molecule BACE1 inhibitor de-
velopment came with the first X-ray co-crystal structure of
BACE1 with a peptidic BACE1 inhibitor [64]. The BACE1
X-ray structure revealed important inhibitor-enzyme inter-
actions that were exploited in rational drug design efforts.
Shortly thereafter, new classes of small molecule BACE1 in-
hibitors were developed that exhibited improved pharma-
cological characteristics, including small molecular weight,
plasma membrane permeability, and better pharmacokinet-
ics [65,66]. However, most second-generation BACE1
inhibitors were substrates of P-glycoprotein, the ATP-
dependent drug efflux pump for xenobiotics in the BBB
[67], and therefore could not reach high concentrations in
the brain.
More recently, potent third-generation small molecule
BACE1 inhibitors have been developed that achieve satis-
factory brain penetration and robust cerebral Aβ reduction
in preclinical animal models. Innovative diverse and com-
plex drug development approaches have been employed to
design current BACE1 inhibitors, which are described indetail in recent reviews [65,66]. Several of these orally
bioavailable BACE1 inhibitor drugs have entered into
human clinical trials (Table 2). Most are in the early clinical
phases and scant information on their progress has been
published, although preliminary trial results for three
BACE1 inhibitor drugs have been reported at recent
conferences and are summarized below.
LY2886721
The pharmaceutical company Eli Lilly was among the first
to develop and test orally bioavailable non-peptidic BACE1
inhibitors in humans. The small molecule BACE1 inhibitor
LY2811376 showed satisfactory pharmacokinetic and phar-
macodynamic characteristics in preclinical animal models
that translated to a Phase 1 clinical trial in humans [68].
However, chronic toxicology studies in rat showing non-
clinical non-target associated pathology in retina and brain
precluded the clinical development of this molecule.
Although it was discontinued, LY2811376 demonstrated the
feasibility of developing a potent brain-penetrant orally bio-
available small molecule BACE1 inhibitor and represented
the first reported translation of reduced CSF biomarkers of
BACE1 cleavage from preclinical animal models to humans.
Lilly advanced a next-generation compound, LY2886721,
into Phase 1 and 2 clinical trials to determine its safety and
tolerability, pharmacokinetics, and pharmacodynamics.
Similar to LY2811376, LY2886721 was a potent orally
bioavailable small molecule BACE1 inhibitor that robustly
decreased levels of Aβ in the brains of preclinical animal
models. However, unlike LY2811376, treatment with
LY2886721 did not appear to be toxic to the retina or brain.
Forty-seven healthy volunteers were given daily oral doses
of either LY2886721 or placebo for 14 days in Phase 1 [69].
Either a multiple ascending dose (5, 15, and 35 mg) or a
single dose (70 mg) followed by a multiple ascending
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(NCT01227252, NCT01534273). Over the course of the
14-day study, LY2886721 was reported to be safe and well
tolerated. Plasma half-life of LY2886721 was ~12 hours,
compatible with once per day dosing. Dose-dependent de-
creases of both plasma and CSF Aβ40 levels resulted from
LY2886721 administration. Aβ40 levels in the CSF were de-
creased up to 74% with the highest dose of LY2886721.
Levels of Aβ42 and sAPPβ in the CSF were both reduced
to a similar extent as CSF Aβ40 by LY2886721. Interest-
ingly, levels of sAPPα, the α-secretase cleavage product,
were increased in CSF [70], an observation that is consist-
ent with BACE1 inhibition, since β- and α-secretase com-
pete for processing of APP. A Phase 1 study of LY2886721
in patients with AD was also conducted (NCT01807026).
The positive Phase 1 trials led to a six-month Phase 2
trial of 35 or 70 mg of LY2886721 dosed orally once per
day in 130 patients with prodromal AD, also known as
amnestic mild cognitive impairment (MCI), or mild AD
(NCT01561430) [71]. Recently, Lilly voluntarily terminated
the Phase 2 trial because a small number of subjects that
were given LY2886721 developed abnormal liver biochem-
istries. The company reported that the LY2886721-related
liver abnormalities did not appear to be associated with the
BACE1 mechanism of action, a conclusion supported by a
normal liver phenotype of BACE1−/− mice. It is not
uncommon that some small molecules in clinical develop-
ment are discontinued because of abnormal liver function
as a non-target related side effect. Thus, the termination of
LY2886721 does not necessarily suggest that BACE1 is not
a viable drug target.
MK-8931
MK-8931, a small molecule BACE1 inhibitor developed by
the pharmaceutical company Merck was tested in 88
healthy volunteers (18–45 years old) as a two-part random-
ized, double-blind, placebo-controlled Phase 1 clinical trial
[72]. Single and multiple (daily for 14 days) oral doses of
MK-8931 were analyzed for safety, tolerability, pharmaco-
kinetics, and pharmacodynamics. In healthy volunteers,
MK-8931 was well tolerated and no serious adverse events
were reported. Determining whether MK-8931 was able to
enter the brain and engage its target, the β-secretase
enzyme, were primary goals of the study. To do so,
biomarkers of BACE1 activity were measured in the CSF,
including Aβ40, Aβ42, and sAPPβ, the latter being the
BACE1-cleaved ectodomain of APP. MK-8931 markedly
reduced levels of Aβ in the CSF in a sustained and dose-
dependent manner. A single oral dose of 100 or 550 mg of
MK-8931 decreased CSF Aβ40 levels by 75% or 92%,
respectively, at 36 hours after dosing. Levels of Aβ42 and
sAPPβ in the CSF were also reduced to similar extents.
Multiple oral dosing of MK-8931 lowered Aβ levels in the
CSF by over 90%. MK-8931 has a plasma half-life of~20 hours, suggesting that a single daily oral dose may
maintain stable drug levels in vivo.
A randomized, double-blind, placebo-controlled Phase
1b trial of MK-8931 in 32 mild to moderate AD patients
(mean age and Mini-Mental State Examination (MMSE),
73 yrs. and 22, respectively) was also conducted for safety,
tolerability, pharmacokinetics, and pharmacodynamics
(NCT01496170) [73]. One of three doses (12, 40, or
60 mg) of MK-8931 or placebo was given once each day
orally for 7 days and levels of Aβ40, Aβ42, and sAPPβ in
the CSF were measured. Similar to the healthy volunteers,
MK-8931 strongly decreased levels of Aβ in the CSF in a
sustained and dose-dependent fashion. Daily dosing of 12,
40, or 60 mg reduced CSF Aβ40 by 57, 79, or 84%,
respectively, and resulted in similar reductions for CSF
Aβ42 and sAPPβ. MK-8931 did not appear to cause ser-
ious adverse events in the AD patients during the course
of the study. Importantly, the MK-8931 Phase 1b results
suggest that the pharmacokinetic and pharmacodynamic
properties of BACE1 inhibitor drugs are not significantly
altered by the presence of high amyloid loads in the brains
of AD patients.
Encouraged by the positive results of the MK-8931 Phase
1 and 1b studies, a Phase 2/3 combined clinical trial (the
EPOCH study, NCT01739348) was started in late 2012.
EPOCH is a 78-week, randomized, placebo-controlled,
parallel-group, double-blind clinical trial to evaluate the
safety and efficacy of 12 or 40 mg/day oral dosing of MK-
8931 versus placebo in mild to moderate AD patients. In
Phase 2 the trial will evaluate 200 AD patients and will
enroll up to 1,700 patients for Phase 3. Primary efficacy
outcomes are the changes from baseline in the Alzheimer’s
Disease Assessment Scale Cognitive Subscale (ADAS-Cog)
and the Alzheimer’s Disease Cooperative Study-Activities
of Daily Living (ADCS-ADL) scores.
A recent interim safety analysis in 200 AD patients
treated with MK-8931 for at least 3 months suggested that
the drug was well tolerated and that the EPOCH study
proceed without changes to the protocol. Enrolment in the
trial has continued with up to 1960 patients expected for
Phase 3. An additional clinical trial (the APECS study,
NCT01953601) has also commenced, consisting of a
104 week randomized, placebo-controlled, parallel-group,
double-blind Phase 3 study to evaluate the safety and
efficacy of 12 mg or 40 mg per day oral dosing of MK-8931
versus placebo in 1500 patients with MCI. The primary
efficacy outcome in APECS is the change from baseline in
the Clinical Dementia Rating Scale-Sum of Boxes (CDR-
SB) score. Secondary outcome substudies are included in
both EPOCH and APECS to measure AD biomarkers,
consisting of cortical amyloid load, CSF Aβ and tau, and
hippocampal volume. The Phase 3 efficacy studies for
EPOCH and APECS are expected to conclude in 2017 and
2018, respectively.
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The AstraZenica BACE1 inhibitor, AZD3293, was recently
tested for safety, tolerability, pharmacokinetics, and effects
on plasma and CSF Aβ levels in healthy young (18–55 yr)
and elderly (55–80 yr) subjects [74]. Phase 1 randomized,
double-blind, placebo-controlled SAD and MAD studies
were conducted. In the SAD study (NCT01739647), 1 to
750 mg doses of AZD3293 were administered to 7 young
cohorts, while an elderly cohort received 15 mg (8 subjects/
cohort). In the MAD study (NCT01795339), multiple
once-daily doses of AZD3293 ranging from 15 to 70 mg
were administered to 5 cohorts (two elderly) for 2 weeks.
AZD3293 was well tolerated with no serious adverse events
reported up to the highest dose given (750 mg) in the SAD
study. The half-life of AZD3293 was 11–20 hours and thus
compatible with once daily dosing. Pharmacokinetic param-
eters of AZD3293 between elderly and young subjects were
indistinguishable. In the MAD study, the 15 or 50 mg doses
reduced CSF Aβ40 and Aβ42 concentrations by a constant
50 or 75%, respectively. Additionally, AZD3293 administra-
tion produced dose-dependent decreases and increases of
sAPPβ and sAPPα concentrations in the CSF, respectively,
that had similar timelines as the reductions in CSF Aβ40
and Aβ42 [75]. The Phase 1 studies of AZD3293 in health
subjects (NCT01739647) and AD patients (NCT01795339)
have been completed, and combined Phase 2/3 trials in
1,551 MCI and mild AD patients are planned (20 mg
or 50 mg doses, 104 week duration, AMARANTH trial
(NCT02245737)). Recently, AstraZenica and Lilly entered
into a partnership to jointly develop AZD3293 for AD.
E2609
The drug company Eisai has developed an orally bio-
available small molecule BACE1 inhibitor, E2609, that has
shown robust lowering of cerebral Aβ in preclinical and
clinical studies. E2609 was first clinically studied in
healthy volunteers in randomized, double-blind, placebo-
controlled Phase 1 trials [76-78]. A single oral ascending
dose (SAD) study (73 subjects) and a 14-day multiple oral
ascending dose (MAD) study (50 subjects) tested E2609 in
two separate Phase 1 clinical trials (NCT01294540 and
NCT01511783, respectively). The SAD study analyzed
plasma Aβ levels following E2609 administration ranging
from 5 to 800 mg (9 cohorts), while the MAD study
measured both plasma and CSF Aβ levels in response to
E2609 doses ranging from 25 to 400 mg (5 cohorts). The
E2609 plasma half-life of 12–16 hours is compatible with
once per day dosing. Each of the two Phase 1 studies
showed robust dose-dependent decreases of levels of Aβ
in the CSF and/or plasma. CSF Aβ levels were reduced up
to 85% at the highest dose of E2609 (400 mg) in the MAD
study. Similar decreases in levels of sAPPβ in the CSF
were observed, while CSF levels of sAPPα were increased.
E2609 appeared to be safe and well tolerated, as no seriousadverse events were reported in either Phase 1 study. Eisai
has recently completed a Phase 1 trial of E2609 in subjects
with MCI or mild AD (NCT01600859), and a Phase 2
clinical trial of E2609 is planned. Recently, Eisai and
Biogen Idec entered into a partnership to jointly develop
E2609 for AD.
Alternative therapeutic approaches for BACE1 inhibition
Although small molecules that directly inhibit BACE1 en-
zyme activity are leading therapeutic approaches, potential
alternative strategies to reduce BACE1 processing of APP
are being explored. As noted, BACE1 levels are significantly
elevated in AD brain and might accelerate the production
of Aβ. Therefore, approaches to lower and normalize
BACE1 levels in the brain might slow AD progression and
avoid possible untoward side effects caused by direct
BACE1 enzyme inhibition. Consequently, efforts are under-
way to elucidate the mechanisms of BACE1 elevation in
AD in order to identify drug targets that could block the
BACE1 increase when inhibited. BACE1 undergoes
complex regulation at the transcriptional, translational, and
post-translational levels, all of which appear to have a role
in elevating BACE1 levels and activity in AD [79-81]. Much
evidence suggests that BACE1 is a stress response protease
that is increased by oxidative stress, inflammation, hypoxia,
and trauma, among other insults that occur in AD
[79,82,83]. Even Aβ itself increases BACE1 levels in neu-
rons [84,85], suggesting a vicious pathogenic cycle whereby
Aβ could accelerate its own production through BACE1
elevation. Which, if any, of these complex multi-layered
regulatory mechanisms might yield therapeutic strategies
for lowering BACE1 levels in AD is unclear, but continuing
research in this important area may reveal promising new
AD drug targets in the future.
Another class of alternative therapeutic strategy for
BACE1 inhibition involves immunotherapy approaches to
reduce BACE1 processing of APP. The first of these strat-
egies employs antibodies directed against the β-secretase
cleavage site of APP that sterically block access of the
BACE1 active site to APP [86,87]. These anti-β-site APP
antibodies decrease Aβ production cultures cells and when
injected i.v. reduce amyloid plaque pathology in the brains
of APP transgenic mice [88]. Other immunotherapy
approaches include anti-BACE1 antibodies that are not
directed against the active site but instead target an exosite
on the surface of the BACE1 catalytic domain that can
allosterically regulate enzyme activity [89,90]. This exosite
is located on structurally adjacent regions of the C, D, and
F loops of the enzyme [91]. Exosite antibody binding to
BACE1 alters structural features and dynamic characteris-
tics near the substrate binging cleft of the enzyme.
Additionally, transport of BACE1 antibodies across the
BBB has been facilitated by engineering one arm of the
antibody to recognize transferrin receptor (TfR), which
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into the brain [92,93]. These bispecific BACE1-TfR anti-
bodies accumulate in the brain and reduce endogenous Aβ
levels in mice to a much greater extent than monospecific
BACE1 antibodies. Moreover, TfR bispecific antibodies
could be useful for treating other neurologic diseases
amenable to immunotherapy. These antibody approaches
are currently in preclinical phases.
Unanswered questions that are relevant to BACE1 inhibitor
clinical trials
Fifteen years after the discovery of the β-secretase enzyme,
the challenges of developing brain-penetrant BACE1 inhibi-
tors have been accomplished and human clinical trials are
underway. This promising development raises hopes that
disease-modifying therapies employing BACE1 inhibition
for AD are within reach. However, important questions
concerning therapeutic goals and outcomes of these trials
remain to be answered:
What degree of BACE1 inhibition will be needed to achieve
efficacy?
The level of BACE1 inhibition required for efficacy in turn
should depend on how much Aβ lowering is necessary and
at what stage of AD to treat (questions discussed further
below). The recently discovered A673T APP mutation that
protects against AD [10] suggests that reducing cerebral Aβ
production by only a modest amount (~20%) could be pre-
ventative, if started before significant amyloid accumulation.
As discussed above, the leading BACE1 inhibitors currently
in clinical trial are capable of this relatively small Aβ
decrease. How BACE1 inhibition translates to Aβ reduction
in the brain is difficult to estimate, although some insight
into this question may be gained by considering experi-
ments in BACE1 knockout mice. Heterozygous BACE1+/−
mice that model 50% therapeutic inhibition of BACE1
exhibit ~20% lowering of cerebral Aβ levels in APP trans-
genic mice [20,33]. Importantly, BACE1+/− mice appear to
be normal, so 50% BACE1 inhibition may circumvent
mechanism-based side effects yet provide sufficient Aβ
reduction for efficacy.
As suggested by the protective A673T mutation, a thera-
peutic approach that reduced BACE1 activity and Aβ levels
by ~50% and ~20%, respectively, would probably need to
start before major amyloid deposition and be maintained
for the remainder of life to prevent or delay the onset of
AD. However, inhibiting BACE1 by more than 50% could
be required if significant amyloid plaque load is present in
the brain at the beginning of treatment. Still, the possibility
exists that no level of BACE1 inhibition, no mater how
strong, would be able to slow the progression of AD once a
certain threshold of amyloid burden is reached. At present,
these arguments are all speculative, as the levels of BACE1
inhibition and Aβ reduction necessary for efficacy inhumans are as yet unknown, although insight into these
parameters might be gleaned following analysis of the
results from the ongoing clinical trials.
It is important to note that cerebral BACE1 levels in AD
patients are increased by several fold over those in normal
individuals [94-97]. Both BACE1 and APP accumulate in
swollen dystrophic neurites that surround amyloid plaques
[34,98,99], suggesting increased peri-plaque Aβ production
that might accelerate amyloid deposition and induce a
vicious pathogenic cycle [100]. If so, normalization of
BACE1 activity in peri-plaque dystrophic neurites may
represent a modest but potentially efficacious therapeutic
goal of BACE1 inhibition. However, elevated concentrations
of BACE1 around plaques might necessitate the administra-
tion of very high BACE1 inhibitor doses in order to signifi-
cantly reduce peri-plaque Aβ generation, if the amyloid
burden is great.
What stage of AD should we administer BACE1 inhibitors?
Cerebral Aβ accumulation has a crucial early role in AD
pathogenesis, as suggested by over 200 FAD mutations [2].
Amyloid deposition appears to begin more than a decade
before the manifestation of cognitive deficits and the
clinical diagnosis of AD [101-103]. Aβ-lowering BACE1
inhibitors are likely to be most effective as a prevention
strategy when administered early in the course of AD,
before significant cerebral amyloid accumulation and
neurodegeneration. Thus, BACE1 inhibitors are analogous
to the cholesterol-lowering statin drugs for the prevention
of heart disease: once significant amounts of cholesterol
have deposited in coronary arteries and major injury to the
heart has occurred, statin administration is unable to re-
verse the damage and provide much benefit for the patient.
AD prevention trials will necessarily involve the enrollment
of thousands of subjects, last for years, and incur enormous
costs. As a result, AD prevention trials might be most
feasible in the context of joint government-industry collab-
orations, such as those being conducted or planned by the
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s
Disease (A4) trial, Alzheimer’s Prevention Initiative (API),
and Dominantly Inherited Alzheimer Network Trials Unit
(DIAN TU). Some AD prevention trials are enrolling
cognitively normal individuals that are genetically at high
risk for developing AD who carry autosomal dominant
FAD mutations (DIAN TU trial) or are homozygous for
the apolipoprotein E ε4 allele (API trial). If BACE inhibitors
are as well tolerated in chronic dosing for AD as the statins
are for lowering serum cholesterol to prevent heart disease,
then treating pre-symptomatic at-risk individuals for AD
prevention is warranted.
Current BACE1 inhibitor trials have enrolled mild and
moderate AD or mild cognitive impairment (MCI), the
latter of which progresses to AD at a rate of ~10-15% per
year [104]. A major advance has been the development of
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CSF Aβ42 measurement as biomarkers for the diagnosis of
prodromal AD [105,106]. Individuals that exhibit significant
amyloid load by PET or have reduced CSF Aβ42 concentra-
tions are likely to develop AD, even though they appear
cognitively normal at the time of testing. Due to the
unavailability of amyloid PET or CSF Aβ42 biomarker test-
ing at the time, past Aβ immunotherapy trials were unable
to exclude subjects that did not have cerebral amyloid accu-
mulation, thus leading to increased variability in cognitive
outcome results and ultimately contributing to the frank
failure of these clinical trials [107]. In contrast, the BACE1
inhibitor clinical trials are enrolling only subjects that are
positive by amyloid PET or CSF Aβ42, which should
decrease data variability and increase the probability of
observing statistically significant differences in cognition
between drug and placebo groups. Periodic amyloid PET or
CSF Aβ42 testing will be conducted to monitor target
engagement and amyloid accumulation over the courses of
the trials. Cognitive performance will also be tested, as this
measure is the gold standard for efficacy in past AD clinical
trials of approved palliative drugs that treat memory symp-
toms. However, as noted above, amyloid deposition appears
to start years before memory deficits are detected with
current tests of cognition. Thus, it might be challenging for
BACE1 inhibitors to alter the trajectory of AD once a large
amount of amyloid has accumulated in the brain, at least
regarding the reduction of cognitive decline.
It is hoped that the levels of BACE1 inhibition and Aβ
reduction necessary for disease modification could be
deduced from data collected at the conclusion of the
current clinical trials. Pharmacodynamic models developed
from this future data might assist in the estimation of the
level of BACE1 inhibition required to achieve efficacious
Aβ reduction for a given cerebral amyloid load and level of
cognitive impairment. These models could also be useful
for the design of future primary and secondary AD preven-
tion trials in pre-symptomatic individuals. At this time, the
relationships between BACE1 inhibition, Aβ reduction,
amyloid load, and cognitive status are not sufficiently well
understood to develop accurate pharmacodynamic models
for estimating the levels of BACE1 inhibition needed at a
given stage of asymptomatic or symptomatic AD.
Will treatment with BACE1 inhibitors cause mechanism-based
side effects?
Although BACE1−/− mice were initially reported to be
normal, recent studies have identified over a dozen BACE1
null phenotypes and substantially more BACE1 substrates
(Table 1, Figure 3), suggesting therapeutic BACE1 inhib-
ition might cause mechanism-based toxicities. That said, it
is unclear to what extent BACE1 null phenotypes in mice
are able to model potential BACE1 inhibitor side effects in
humans, for several reasons. First, BACE1 null phenotypescould relate to functions of BACE1 either during develop-
ment or in adulthood, since BACE1−/− mice lack BACE1
from conception. For example, the major proportion of
myelination occurs during development and is completed
when adulthood is reached [108], indicating that hypomye-
lination as a result of abrogated BACE1 processing of
NRG1 in BACE1−/− mice is a developmental phenotype.
Consequently, BACE1 inhibition in the adult might not
have an impact on myelination, unless re-myelination fol-
lowing injury becomes necessary. In contrast, neurogenesis
and axon guidance are ongoing processes that occur in
specific neuronal subpopulations that regenerate through-
out life [38,46], suggesting the possibility that BACE1−/−
abnormalities in neurogenesis and axon targeting are adult
phenotypes and that BACE1 inhibitor treatment might lead
to similar defects. Additionally, it is possible that compen-
sation from other proteases during development could
mitigate the effects of BACE1 null mutation, in which case
BACE1 inhibitor treatment in humans might have more se-
vere side effects than indicated by BACE1−/− mice. Given
these arguments, comprehensive analyses of BACE1−/−
mice should help to parse developmental verses adult
BACE1 null phenotypes for the estimation of BACE1
inhibitor side effect risk.
The risk of BACE1 mechanism-based toxicities will
depend in large part on the degree of therapeutic BACE1
inhibition. At one extreme, BACE1−/− mice model 100%
BACE1 inhibition, but this level of inhibition will never be
achieved by BACE1 inhibitor treatment in practice, thus
reducing the chance of side effects. However, AD patients
are elderly and often frail, thus increasing the risk of serious
adverse events caused by BACE1 inhibition. Moreover,
BACE1 inhibitors must be chronically administered, neces-
sitating a high level of safety. Ongoing and future BACE1
inhibitor clinical trials will ultimately answer these ques-
tions. It is anticipated that a therapeutic window will be
discovered in which an empirically determined range of
BACE1 inhibitor doses can balance tolerable mechanism-
based side effects with sufficient reduction of cerebral Aβ
levels for efficacy.
The statins are useful as a group for modeling the clin-
ical development of BACE1 inhibitors, as indicated by the
fact that the statin clinical trials determined a therapeutic
dose window of HMG Co-A reductase inhibitor that
effectively decreased serum cholesterol levels to prevent
heart disease in the presence of tolerable side effects. We
are now in the early phases of this clinical development
model for BACE1 inhibitors. Regardless of the final out-
comes of the current BACE1 inhibitor trials, invaluable
knowledge will be gained about the quantitative and
temporal relationships between BACE1 inhibition, Aβ
reduction, amyloid burden, and cognitive function in
humans, which will be used for future clinical development
of BACE1 inhibitors for AD.
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As the β-secretase enzyme that initiates the production of
Aβ, BACE1 is a key therapeutic target for AD. The protect-
ive A673T APP mutation in humans and genetic deletion
of BACE1 in mice both decrease Aβ generation via reduced
β-secretase processing of APP, providing strong proof of
concept that BACE1 inhibition should be efficacious for
AD. However, BACE1 null mice exhibit multiple complex
neurological phenotypes (Table 1), suggesting that BACE1
inhibitor drugs might cause mechanism-based side effects
involving hypomyelination, seizure, axon guidance defects,
memory deficits, neurogenesis abnormalities, and neuro-
degeneration, and potentially others, resulting from insuffi-
cient BACE1 processing of a growing list of BACE1
substrates in neurons. Which, if any, of these BACE1 null
phenotypes model BACE1 inhibitor side effects in humans
remains to ne determined.
Despite the challenges of BACE1 inhibitor drug develop-
ment over the past 15 years since the discovery of BACE1,
the recent introduction of several BACE1 inhibitors into
clinical trials has refocused attention on this promising
therapeutic approach for AD. To date, Merck’s MK-8931
has advanced the farthest to Phase 2/3, while the other
drugs including those from AstraZeneca, Eisai, and Pfizer,
among others, are in Phases 1 and 2. These compounds are
potent, achieving up to ~90% CSF Aβ reduction. Addition-
ally, they are well-tolerated for the most part, although two
BACE1 inhibitors have recently been terminated due to
toxicity that might not be related to the BACE1 mechanism
of action.
The most challenging questions for BACE1 inhibitor clin-
ical development concern the level of BACE1 inhibition
and the stage of AD at which to treat for optimal efficacy.
Hypothetical arguments based on the A673TAPP mutation
and BACE1+/− mice suggest that ~50% BACE1 inhibition
might achieve ~20% Aβ reduction, which could prevent
AD if begun well before significant amyloid deposition.
However, it is unclear whether any level of BACE1 inhib-
ition can be effective if major amyloid accumulation is
present in the brain. Amyloid PET imaging, CSF Aβ42
measurement, and other biomarker studies suggest that
amyloid deposition starts years, even decades, before the
clinical diagnosis of dementia. Moreover, the relationships
between amyloid burden and cognitive impairment are not
sufficiently well understood to determine the stage of AD
that BACE1 inhibitor treatment would be most effective.
Results from ongoing biomarker studies, future treatment
and prevention trial, and pharmacodynamic modeling are
expected to establish the appropriate level of BACE1 inhib-
ition and stage of AD for optimal efficacy. Like the statins
for hypercholesterolemia, the hope is that a therapeutic
window of BACE1 inhibitor doses might be found that re-
duces cerebral Aβ levels enough for efficacy, yet maintains
sufficient BACE1 activity for the avoidance of side effects.When eventually published, the results of the current
BACE1 inhibitor clinical trials will prove invaluable for
solving these important questions. We are at a crucial
juncture in BACE1 inhibitor drug development, and the
therapeutic potential of BACE1 inhibition for AD will be
definitively answered in the not too distant future.
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